Introduction

I
mproving antibiotic use is necessary to curb antibiotic resistance. Wide variations in outpatient antibiotic use are well described, including some studies having shown differences between general practitioners (GPs). [1] [2] [3] Quality indicators assessing in detail the use of antibiotics among GPs would then be useful to target antibiotic stewardship interventions, but few indicators have been studied in the literature. [2] [3] [4] European surveillance of antimicrobial consumption (ESAC; www.esac.ua.ac.be) developed evidence-based disease-specific quality indicators, 4 but in France, as in other countries, no information system exists that provides easy access to data linking drug use to clinical conditions. However, data regarding types and quantity of antibiotics prescribed are easily available from the databases of the National Health Insurance (NHI). Using these reimbursement data, we performed a cross-sectional study in 2009 in south-eastern France to describe in detail GPs' antibiotic prescribing profiles in a standardized way without clinical data. For that purpose, we adapted at the GP level a set of 12 valid drug-specific quality indicators initially developed by Coenen et al. to compare ESAC data on outpatient antibiotic use between European countries. 5 
Methods
We conducted the study in adults aged !16 years in south-eastern France (Provence-Alpes-Cô te-d'Azur region) in 2009. In France, patients pay health service fees, which are refunded by the NHI. Everyone, even those with low or no income, is covered by the NHI program. All antibiotics are subjected to reimbursement by the NHI. Data were collected from the outpatient reimbursement database of the General Health Insurance Fund, which covers salaried workers and socio-professional groups, such as the unemployed, i.e. 73% of the population in our region in 2009. Each time a prescribed drug was dispensed, information on the drug dispensed, the prescribing physician and the patient identification number are recorded and electronically sent to the NHI, with a procedure preserving anonymity at the patient and physician levels.
For this study, data included each occasion on which antibiotics (J01 code according to the anatomical therapeutic chemical classification) were dispensed in 2009 and were expressed as defined daily doses (DDD, http://www.whocc.no/). We did not include antibiotic prescriptions in children <16 years because DDD underestimate the quantity of antibiotics prescribed in this population, unless presented by age class, but the age distribution of the patients <16 years at the GP level was unavailable.
From the 6025 GPs practicing in south-eastern France in 2009, we excluded those having a particular type of exercise (e.g. homeopathy or acupuncture, n = 584), and those with a very low or a very high level of activity [<200 patients (n = 437) and >10 000 patients (n = 59), respectively, seen in 2009], to obtain a relatively homogenous sample of GPs.
We analysed antibiotic prescriptions at the GP level and expressed them as DDD/1000 active adult patients/day, further abbreviated as DPD, instead of DDD/1000 inhabitants/day as usually done at country level by ESAC; 5 active patients were patients seen at least once in 2009 by the GP. We then further excluded GP outliers regarding total antibiotic prescriptions (<1st percentile or >99th percentile), leaving 4971 GPs to be finally included in the study.
A set of 12 drug-specific quality indicators was calculated at the GP level, using the ESAC's methodology (table 1) . 5 Medians and interquartile ranges (IQR) were used to describe the 12 drug-specific quality indicators. Analyses were performed using SAS version 9.1 Õ .
Results
Results regarding the 12 drug-specific quality indicators calculated at the GP level (table 1) showed that GPs prescribed, for 1000 active adult patients, an average of 11 DDD of antibiotics each day with a rather important IQR (7.46-14.55), demonstrating wide variations of prescribing between GPs. The indicator assessing seasonal variation of total antibiotic use showed that total antibiotic prescriptions were on average 50% more frequent in winter compared with summer, with wide variations between GPs.
Discussion
We could adapt the 12 ESAC drug-specific quality indicators at the GP level. This allowed us to describe in detail each GP's antibiotic prescribing profile in a standardized way. Substantial heterogeneity in antibiotic prescribing among French GPs was observed for all indicators, including seasonal variation of antibiotic use. Our main objective was to describe antibiotic prescribing profiles at the GP level. Our data can nevertheless be looked at globally, at the region level, to compare them with the ESAC data published in the literature. Comparing our results with national or European data is not possible for indicators evaluating crude antibiotic use (i.e. the first five indicators) because our selected population is different. As an example, the French mean consumption of antibacterials for systemic use ('TotalAB') was 29.6 DDD/1000 inhabitants/day in 2009 (all outpatients and all prescribers), 6 whereas the median value for this indicator in our study in 2009 was 10.8 DDD/1000 active adult patients/day at the GP level (corresponding to 10.7 DDD of antibiotics/1000 inhabitants/day prescribed by the selected GPs at our region level). However, the seven other indicators are much more comparable because they use percentages or ratios. As examples, values for '%Penicillins combinations' indicator (combination of penicillins, including beta-lactamase inhibitor) were 21.95% in France in 2009 vs. 19.0% in our study, and values for '%fluoro-quinolones' indicator were 6.5% in France vs. 9.1% in our study. Indicators targeting seasonal variations of antibiotic use can also be compared with European values (in 2009); seasonal variations are more pronounced in our study ('Total AB seasonal variation': %26% in Europe vs 49% in our study, and 'Quinolone seasonal variation': %8% vs 25%). 6 Winter peaks of antibiotic use are thought to represent treatments of respiratory tract infections, which are mainly viral, suggesting that seasonal variation of antibiotic use is a good indicator of antibiotic misuse. 7 Our study brings original data and is strengthened by the use of thoroughly validated drug-specific quality indicators, developed at the European level. 5 Our work has, however, some limitations. Firstly, we used DDD because this standardized unit of measure is recommended worldwide to ensure comparability of the results; however, the same DDD/1000 active patients/day result could correspond either to GPs prescribing few antibiotic courses for long durations, or to GPs prescribing many courses but for shorter durations. Secondly, these indicators calculated at the GP level allow describing each GP's antibiotic prescribing profile, but clinical data are necessary to definitely assess the appropriateness of these antibiotic prescriptions.
In conclusion, drug-specific indicators could be calculated using reimbursement data to describe outpatient antibiotic prescriptions at the GP level and showed wide variations in antibiotic use among French GPs. These indicators could be used by each GP as a self-assessment tool, in comparison with other GPs' results used as a way to motivate change. Further investigations are however needed to look for associations of each of these indicators with antibiotic misuse based on medical records review, or on a comparison with disease-specific quality indicators. In countries where data linking antibiotic prescriptions with patients' age/gender and diagnosis are easily available for all GPs through a computerized system, the set of 21 evidence-based valid disease-specific quality indicators recently developed by the ESAC project group can be used. 4 If some of the 12 drug-specific indicators we calculated proved to be associated with antibiotic misuse at the GP level, they could be useful for benchmarking or pay-for-performance purposes.
